spacer
home > ebr > spring 2002 > 2nd annual bia european ceo & investor conference - 27th-28th november 2001, london
PUBLICATIONS
European Biopharmaceutical Review

2nd Annual BIA European CEO & Investor Conference - 27th-28th November 2001, London

The theme of the BIA's successful 2nd Annual CEO & Investor Conference, held in London towards the end of last year was 'From Promise to Products'. This was a timely choice given the re-focus of investor sentiment which underscored the market conditions for life science investing throughout 2001 and has continued in the first quarter of 2002. The name of the game is developing products to deliver long-term and sustainable value (nothing new there, of course) and this was the underlying proposition behind all of the elements of this two-day conference. Run by the BIA in partnership with Technology Vision Group (TVG), the aim of the CEO & Investor Conference was to provide a platform for both public and private European companies and their investors to present to, and engage with, each other on the product delivery question. This assumed various structured forms including moderated CEO roundtable discussions, which were also co-ordinated to illustrate different case scenarios for acceleration towards products. In addition, there were themed investor panels that focused on innovation in both science and partnering plus the leveraging of intellectual property assets to raise finance. Beyond the parallel CEO and investor panels, the third track featured a series of European company presentations from a range of public and private European companies across multiple technology platforms and therapeutic areas - all with one element in common: the drive towards products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark and Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement